Eric Venker - 10 Nov 2026 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Reporting relationship: President & Immunovant CEO
Issuer ticker: ROIV
Reported as of: 10 Nov 2026
Net transaction value: -$7,617,074
SEC form: 4
Accepted by SEC: 12 Nov 2026, 19:00:19 UTC
Prior SEC filing: 05 Nov 2026
Source filing: View source filing
Reporting owner signature: By: /s/ Sam Kaplan, as Attorney-in-Fact for Eric Venker

Filing notes and source

Key filing fact

Eric Venker filed Form 4 for Roivant Sciences Ltd. (ROIV) on 12 Nov 2026.

Key facts

This page summarizes Eric Venker's Form 4 filing for Roivant Sciences Ltd. (ROIV).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 12 Nov 2026, 19:00.

Change

Previous filing in this sequence was filed on 05 Nov 2026.
Current net transaction value: -$7,617,074.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001801917 Primary reporting owner

Venker Eric

Relationship: President & Immunovant CEO
Address: C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM
Signature: By: /s/ Sam Kaplan, as Attorney-in-Fact for Eric Venker
Signature date: 12 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ROIV transaction

Common Shares

Sale

Transaction value: -$6,397,365
Shares: -158,194
Change %: -16%
Price: $40.44
Shares after: 840,960
Date: 10 Nov 2026
Ownership: Direct
Footnotes: F1

ROIV transaction

Common Shares

Sale

Transaction value: -$1,219,709
Shares: -29,749
Change %: -3.5%
Price: $41.00
Shares after: 811,211
Date: 10 Nov 2026
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 to $40.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 30, 2026.

Footnote F2

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.93 to $41.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 30, 2026.